Olema Pharmaceuticals (OLMA) Price & Analysis

Compare

760 Followers

OLMA Stock Chart & Stats

Day’s Range― - ―

52-Week Range$2.86 - $13.51

Previous CloseN/A

Volume1.27M

Average Volume (3M)1.36M

Market Cap

$725.46M

Enterprise Value-$70.36M

Total Cash (Recent Filing)$361.91M

Total Debt (Recent Filing)$1.75M

Price to Earnings (P/E)―

Beta1.81

Next Earnings

Nov 11, 2025

EPS Estimate

-0.48

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.51

Shares Outstanding68,634,330

10 Day Avg. Volume1,329,646

30 Day Avg. Volume1,361,344

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap-0.10

Enterprise Value/Revenue-193.29

Enterprise Value/Gross Profit1.72K

Enterprise Value/Ebitda0.45

Forecast

1Y Price Target

$23.60

Price Target Upside123.27% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering7

Bulls Say, Bears Say

Bulls Say

Clinical TrialsThe OPERA-01 trial is designed to showcase the efficacy of palazestrant in both ESR1-mutated and ESR1 wild-type populations, aiming for broad FDA approval.

Drug EfficacyPalazestrant is the only oral SERD that can safely achieve high exposures in combinations to accomplish complete ER saturation and inactivation.

PartnershipsOlema's recently disclosed clinical trial collaboration and supply agreement regarding Pfizer's aformociclib, in combination with their oral complete estrogen receptor (ER) antagonist (CERAN) and selective estrogen receptor degrader (SERD), palazestrant (OP-1250), suggests that Pfizer is still interested in the oral SERD space.

Bears Say

Competitive LandscapeEmerging competitor data should see value accrue to OLMA even if behind because of palazestrant’s superior properties.

Market ValuationOLMA shares are materially undervalued in the refractory setting alone.

Regulatory ChallengesA pivotal trial involving an oral SERD with atirmociclib might conflict with the FDA's view on novel-on-novel combinations in advanced/metastatic ER+ breast cancer.

Olema Pharmaceuticals News

Olema Oncology initiated with a Buy at Guggenheim

Guggenheim initiated coverage of Olema Oncology (OLMA) with a Buy rating and $20 price target The firm sees...

5d ago

OLMA

Oppenheimer reiterates Buy on Olema, sees evERA readthrough to persevERA

Oppenheimer notes that Olema (OLMA) shares are up today, likely on news that Roche’s (RHHBY) evERA trial was...

21d ago

CHRO

OLMA

Oppenheimer reiterates Buy on Olema, sees evERA readthrough to persevERA

Oppenheimer analyst Matthew Biegler notes that Olema (OLMA) shares are up today, likely on news that Roche’s (RHHBY)...

21d ago

CHRO

OLMA

Promising Potential of Olema Pharmaceuticals’ Palazestrant in ESR1 Patient Treatment Drives Buy Rating

Emily Bodnar, an analyst from H.C. Wainwright, maintained the Buy rating on Olema Pharmaceuticals. The associated price target...

17d ago

OLMA

Olema Pharmaceuticals: Strategic Positioning and Promising Outlook in the Oral SERD Market

In a report released today, Sam Slutsky from LifeSci Capital maintained a Buy rating on Olema Pharmaceuticals, with...

25d ago

OLMA

Oppenheimer says Olema collaboration with Pfizer could lead to bidding war

Oppenheimer analyst Matthew Biegler says the firm had a chance to speak with Olema Oncology (OLMA) management after...

1M ago

NVS

PFE

Buy Recommendation for Olema Pharmaceuticals Driven by Strategic Collaborations and Promising Clinical Developments

Emily Bodnar, an analyst from H.C. Wainwright, maintained the Buy rating on Olema Pharmaceuticals. The associated price target...

1M ago

OLMA

Strategic Collaboration with Pfizer Boosts Olema Pharmaceuticals’ Prospects in ER+ Breast Cancer Treatment

Analyst Sam Slutsky from LifeSci Capital maintained a Buy rating on Olema Pharmaceuticals and keeping the price target...

1M ago

OLMA

Olema Pharmaceuticals Partners with Pfizer for New Trial

Olema Pharmaceuticals ( ($OLMA) ) has provided an update. On September 2, 2025, Olema Pharmaceuticals announced a new...

1M ago

OLMA

Olema Oncology announces new trial agreement with Pfizer

Olema Pharmaceuticals (OLMA) announced a new clinical trial collaboration and supply agreement with Pfizer (PFE) in metastatic breast...

1M ago

PFE

OLMA

Olema Pharmaceuticals: Strategic Advancements and Market Potential in Oncology Drive Buy Rating

TD Cowen analyst Tyler Van Buren has maintained their bullish stance on OLMA stock, giving a Buy rating...

2M ago

OLMA

Promising Efficacy and Strategic Partnerships Drive Buy Rating for Olema Pharmaceuticals

Olema Pharmaceuticals, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Emily Bodnar from...

2M ago

OLMA

Citi ups Olema target, adds ‘upside catalyst watch’

Citi raised the firm’s price target on Olema Oncology (OLMA) to $21 from $20 and keeps a Buy...

2M ago

OLMA

Olema Pharmaceuticals Advances Breast Cancer Therapies

Olema Pharmaceuticals, Inc. ( ($OLMA) ) has released its Q2 earnings. Here is a breakdown of the information...

2M ago

OLMA

OLMA FAQ

What was Olema Pharmaceuticals’s price range in the past 12 months?

Olema Pharmaceuticals lowest stock price was $2.86 and its highest was $13.51 in the past 12 months.

What is Olema Pharmaceuticals’s market cap?

Olema Pharmaceuticals’s market cap is $725.46M.

When is Olema Pharmaceuticals’s upcoming earnings report date?

Olema Pharmaceuticals’s upcoming earnings report date is Nov 11, 2025 which is in 29 days.

How were Olema Pharmaceuticals’s earnings last quarter?

Olema Pharmaceuticals released its earnings results on Aug 11, 2025. The company reported -$0.51 earnings per share for the quarter, missing the consensus estimate of -$0.376 by -$0.134.

Is Olema Pharmaceuticals overvalued?

According to Wall Street analysts Olema Pharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Olema Pharmaceuticals pay dividends?

Olema Pharmaceuticals does not currently pay dividends.

What is Olema Pharmaceuticals’s EPS estimate?

Olema Pharmaceuticals’s EPS estimate is -0.48.

How many shares outstanding does Olema Pharmaceuticals have?

Olema Pharmaceuticals has 68,634,330 shares outstanding.

What happened to Olema Pharmaceuticals’s price movement after its last earnings report?

Olema Pharmaceuticals reported an EPS of -$0.51 in its last earnings report, missing expectations of -$0.376. Following the earnings report the stock price went up 16.193%.

Which hedge fund is a major shareholder of Olema Pharmaceuticals?

Currently, no hedge funds are holding shares in OLMA

Olema Pharmaceuticals Stock Smart Score

Outperform

Fundamentals

Return on Equity

-49.72%

Trailing 12-Months

Asset Growth

50.07%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Olema Pharmaceuticals

Olema Pharmaceuticals, Inc. (OLMA) is a clinical-stage biopharmaceutical company focused on developing targeted therapies for women's cancers. The company's primary focus is on the discovery and development of therapies for hormone receptor-positive breast cancer. Olema's lead product candidate, OP-1250, is designed to be a potential best-in-class complete estrogen receptor antagonist (CERAN) that inhibits estrogen receptor-positive (ER+) cancer growth.

Olema Pharmaceuticals (OLMA) Earnings & Revenues

Historic Earnings Reports

OLMA Stock 12 Month Forecast

Average Price Target

$23.60

▲(123.27% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","29":"$29","8.75":"$8.75","15.5":"$15.5","22.25":"$22.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":28,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$28.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":23.6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$23.60</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$20.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,8.75,15.5,22.25,29],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.04,12.344615384615384,13.649230769230769,14.953846153846154,16.25846153846154,17.563076923076924,18.86769230769231,20.17230769230769,21.47692307692308,22.78153846153846,24.08615384615385,25.39076923076923,26.695384615384615,{"y":28,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.04,12.006153846153845,12.972307692307691,13.938461538461539,14.904615384615385,15.87076923076923,16.836923076923078,17.803076923076922,18.76923076923077,19.735384615384618,20.701538461538462,21.66769230769231,22.633846153846157,{"y":23.6,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.04,11.72923076923077,12.418461538461537,13.107692307692307,13.796923076923076,14.486153846153845,15.175384615384615,15.864615384615384,16.553846153846152,17.243076923076924,17.932307692307692,18.621538461538464,19.310769230769232,{"y":20,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":11.8,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.3,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.62,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.21,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.83,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.11,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.37,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.34,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.29,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.38,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.33,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.47,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.04,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >